Matches in SemOpenAlex for { <https://semopenalex.org/work/W2526571213> ?p ?o ?g. }
- W2526571213 abstract "Abstract Abstract 2535 Background: Minimal residual disease is well established as an important prognostic parameter in a number of hematologic diseases and is used for stratification and treatment decisions in adult and childhood acute lymphoblastic leukaemia (ALL). DNA- based PCR analysis of Ig-/TCR-rearrangements have been well standardised during the last decade, resulting in robust systems for MRD analysis with an intra- and inter-assay variability of less than half a log and low false positivity. In Ph+ALL, MRD analysis relies on RNA-based RT-PCR techniques that are highly sensitive but as yet lack standardisation between laboratories. Since laboratories differ substantially in both their methodology and analysis strategy, interpretation and meaningful comparison of results between laboratories and from different studies is difficult or impossible. Moreover, and in contrast to CML, there are no generally accepted definitions of molecular response that could identify thresholds on which to base therapeutic decisions. Aims: To assess i) the variability of BCR-ABL quantification between laboratories with recognized expertise in bcr-abl analysis, ii) identify optimal laboratory methods and iii) to standardize analysis and interpretation of RT-PCR results for Ph+ALL, the EWALL and ESG-MRD-ALL consortia initiated a multinational project for quality assurance involving more than 30 laboratories from 14 countries worldwide. We here report the results of the first six m-BCR-ABL laboratory control rounds, performed between march 2008 and august 2011, that focussed on inter-intraassay variability of rt-PR techniques, comparison of housekeeping genes, plasmids, platforms and reagents. Methods: Serial dilutions of the BCR-ABL positive cell line Sup B15 with the BCR-ABL negative cell line Nalm 6 covering 5 logs were produced. In the 6 lab rounds, 1355 aliquots, each generated from with a total amount of 5 × 10E+06 cells in a final volume of 1 ml were produced, stabilized in TRIZOL or buffer RLT and frozen at −20°C until shipment or centralized isolation of RNA and reverse transcribed. Participants were asked to process the material using predefined procedures. Results: In the first QC round a major finding was the high variability in RNA-yield between laboratories despite using the same extraction method, with an up to 3 log difference in ABL copy numbers. In addition, there was rare false-positivity and false negativity (specifity 94.8%). With centrally produced cDNA the variability improved and there was a lower frequency of false-positivity reaching 100% specifity in QC 2. By using standardized assays, in 12 of 33 laboratories no conversion factor is needed, 20 of 33 laboratories are at the moment within one log difference when comparing the BCR-ABL/ABL ratios. Comparison of housekeeping genes (ABL/GUS) revealed non-linearity at high transcript levels resulting in an underestimation of intraindividual log reductions and may be relevant when assessing disease prognosis. The quantitative range was generally above 10E-04. Conclusion: Initiation of laboratory control rounds and implementation of standardized methodology improved the variability and reduced the frequency of false-positive results. Sensitivity of current techniques is still unsatisfactory for diseases with aggressive growth kinetics such as Ph*ALL. Further standardisation of technical and analytical methodology will provide the basis for defining levels of molecular remission and relapse and help to ensure comparability between laboratories and clinical trials at the European level. Disclosures: Goekbuget: Micromet: Consultancy. Ottmann:Novartis Corporation: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding." @default.
- W2526571213 created "2016-10-07" @default.
- W2526571213 creator A5002941716 @default.
- W2526571213 creator A5005392796 @default.
- W2526571213 creator A5006048101 @default.
- W2526571213 creator A5009884108 @default.
- W2526571213 creator A5009969425 @default.
- W2526571213 creator A5012014901 @default.
- W2526571213 creator A5012805294 @default.
- W2526571213 creator A5013998402 @default.
- W2526571213 creator A5014998105 @default.
- W2526571213 creator A5020546928 @default.
- W2526571213 creator A5023137678 @default.
- W2526571213 creator A5027341200 @default.
- W2526571213 creator A5029712912 @default.
- W2526571213 creator A5035072666 @default.
- W2526571213 creator A5042206697 @default.
- W2526571213 creator A5042712999 @default.
- W2526571213 creator A5043116632 @default.
- W2526571213 creator A5043445949 @default.
- W2526571213 creator A5045283637 @default.
- W2526571213 creator A5055821837 @default.
- W2526571213 creator A5057084037 @default.
- W2526571213 creator A5059439179 @default.
- W2526571213 creator A5060457186 @default.
- W2526571213 creator A5061054700 @default.
- W2526571213 creator A5064255883 @default.
- W2526571213 creator A5064625563 @default.
- W2526571213 creator A5066213019 @default.
- W2526571213 creator A5068363133 @default.
- W2526571213 creator A5076365826 @default.
- W2526571213 creator A5076399981 @default.
- W2526571213 creator A5078221812 @default.
- W2526571213 creator A5079520283 @default.
- W2526571213 creator A5081622399 @default.
- W2526571213 creator A5082725388 @default.
- W2526571213 creator A5083604787 @default.
- W2526571213 creator A5086305480 @default.
- W2526571213 creator A5090910971 @default.
- W2526571213 date "2011-11-18" @default.
- W2526571213 modified "2023-10-18" @default.
- W2526571213 title "International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia" @default.
- W2526571213 doi "https://doi.org/10.1182/blood.v118.21.2535.2535" @default.
- W2526571213 hasPublicationYear "2011" @default.
- W2526571213 type Work @default.
- W2526571213 sameAs 2526571213 @default.
- W2526571213 citedByCount "5" @default.
- W2526571213 countsByYear W25265712132012 @default.
- W2526571213 countsByYear W25265712132013 @default.
- W2526571213 countsByYear W25265712132014 @default.
- W2526571213 countsByYear W25265712132015 @default.
- W2526571213 crossrefType "journal-article" @default.
- W2526571213 hasAuthorship W2526571213A5002941716 @default.
- W2526571213 hasAuthorship W2526571213A5005392796 @default.
- W2526571213 hasAuthorship W2526571213A5006048101 @default.
- W2526571213 hasAuthorship W2526571213A5009884108 @default.
- W2526571213 hasAuthorship W2526571213A5009969425 @default.
- W2526571213 hasAuthorship W2526571213A5012014901 @default.
- W2526571213 hasAuthorship W2526571213A5012805294 @default.
- W2526571213 hasAuthorship W2526571213A5013998402 @default.
- W2526571213 hasAuthorship W2526571213A5014998105 @default.
- W2526571213 hasAuthorship W2526571213A5020546928 @default.
- W2526571213 hasAuthorship W2526571213A5023137678 @default.
- W2526571213 hasAuthorship W2526571213A5027341200 @default.
- W2526571213 hasAuthorship W2526571213A5029712912 @default.
- W2526571213 hasAuthorship W2526571213A5035072666 @default.
- W2526571213 hasAuthorship W2526571213A5042206697 @default.
- W2526571213 hasAuthorship W2526571213A5042712999 @default.
- W2526571213 hasAuthorship W2526571213A5043116632 @default.
- W2526571213 hasAuthorship W2526571213A5043445949 @default.
- W2526571213 hasAuthorship W2526571213A5045283637 @default.
- W2526571213 hasAuthorship W2526571213A5055821837 @default.
- W2526571213 hasAuthorship W2526571213A5057084037 @default.
- W2526571213 hasAuthorship W2526571213A5059439179 @default.
- W2526571213 hasAuthorship W2526571213A5060457186 @default.
- W2526571213 hasAuthorship W2526571213A5061054700 @default.
- W2526571213 hasAuthorship W2526571213A5064255883 @default.
- W2526571213 hasAuthorship W2526571213A5064625563 @default.
- W2526571213 hasAuthorship W2526571213A5066213019 @default.
- W2526571213 hasAuthorship W2526571213A5068363133 @default.
- W2526571213 hasAuthorship W2526571213A5076365826 @default.
- W2526571213 hasAuthorship W2526571213A5076399981 @default.
- W2526571213 hasAuthorship W2526571213A5078221812 @default.
- W2526571213 hasAuthorship W2526571213A5079520283 @default.
- W2526571213 hasAuthorship W2526571213A5081622399 @default.
- W2526571213 hasAuthorship W2526571213A5082725388 @default.
- W2526571213 hasAuthorship W2526571213A5083604787 @default.
- W2526571213 hasAuthorship W2526571213A5086305480 @default.
- W2526571213 hasAuthorship W2526571213A5090910971 @default.
- W2526571213 hasConcept C104317684 @default.
- W2526571213 hasConcept C126322002 @default.
- W2526571213 hasConcept C142724271 @default.
- W2526571213 hasConcept C143660080 @default.
- W2526571213 hasConcept C143998085 @default.
- W2526571213 hasConcept C150194340 @default.
- W2526571213 hasConcept C170493617 @default.
- W2526571213 hasConcept C184112429 @default.
- W2526571213 hasConcept C203014093 @default.
- W2526571213 hasConcept C204787440 @default.
- W2526571213 hasConcept C2778461978 @default.